Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

41.98 +0.23 (+0.55%)
Streaming Delayed Price Updated: 1:28 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 259,926
Open 41.41
Bid (Size) 41.97 (2)
Ask (Size) 42.02 (4)
Prev. Close 41.75
Today's Range 41.28 - 42.07
52wk Range 32.69 - 48.82
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79
The Relative Strength Rating for Ionis Pharmaceuticals stock moved into a new percentile Wednesday, as it got a lift from 65 to 79. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
 
Via Benzinga

Performance

YTD
+11.71%
+11.71%
1 Month
+15.97%
+15.97%
3 Month
+15.81%
+15.81%
6 Month
+7.70%
+7.70%
1 Year
+23.40%
+23.40%

More News

Read More
Recap: Ionis Pharmaceuticals Q1 Earnings
Via Benzinga
Ionis Pharmaceuticals's Earnings Outlook
Via Benzinga
Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA
Via Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
Analyst Ratings for Ionis Pharmaceuticals
Via Benzinga
Ionis Pharmaceuticals's Earnings Outlook
Via Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
What's Going On With Biogen Stock Tuesday?
Via Benzinga
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs
Via Benzinga
3 Biotech Stocks to Sell Before They’re 6 Feet Under
Via InvestorPlace
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
Via Benzinga
Could This Rare-Disease Drug Candidate Become a Blockbuster?
Via The Motley Fool
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
Via Benzinga
The Latest Analyst Ratings for Ionis Pharmaceuticals
Via Benzinga
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
Via Benzinga
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Via Investor's Business Daily
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
Via Benzinga
Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile'
Via Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
Via Investor's Business Daily
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
From Royalty Pharma plc
Via GlobeNewswire
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
From Biogen Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.